Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $0.74 Analyst target: $6.00 Upside: 710.81%
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in developing novel T cell immunotherapeutics to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company is headquartered in Harwell, the United Kingdom.
See the full interactive analysis & chart →Informational only — not investment advice.